NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

November 15, 2026

Conditions

Gastric CancerPancreatic CancerSolid Tumor

Interventions

BIOLOGICAL

KD-496

Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells

Trial Locations (1)

Beijing Cancer Hospital, Beijing

All Listed Sponsors

collaborator

KAEDI

OTHER

lead

Peking University

OTHER

NCT06134960 - NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor | Biotech Hunter | Biotech Hunter